Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia

References

• Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–7. doi:10.1182/bloodadvances.2019000966.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86. doi:10.1182/blood-2009-06-225565.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207. doi:10.1182/blood-2010-08-302984.
   PubMed Web of Science ®Google Scholar
• Matschke J, Müller-Beissenhirtz H, Novotny J, Vester I, Hertenstein B, Eisele L, Lax H, Ose C, Dührsen U. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naïve adult patients with immune thrombocytopenia: EIS 2002 study. Acta Haematol. 2016;136(2):101–7. doi:10.1159/000445420.
   PubMed Web of Science ®Google Scholar
• Karpatkin S. Autoimmune thrombocytopenic purpura. Blood. 1980;56(3):329–43. doi:10.1182/blood.V56.3.329.329.
   PubMed Web of Science ®Google Scholar
• Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood. 1999;94(1):365–7. doi:10.1182/blood.V94.1.365.413a46_365_367. PMID: 10381535.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Lakkaraja M. Thrombopoietic agents: there is still much to learn. Presse Med. 2014;43(4 Pt 2):e69–78. doi:10.1016/j.lpm.2014.02.008.
   PubMedGoogle Scholar
• Wörmann B. Clinical indications for thrombopoietin and thrombopoietin-receptor agonists. Transfus Med Hemother. 2013;40(5):319–25. doi:10.1159/000355006.
   PubMed Web of Science ®Google Scholar
• Zhao YQ, Wang QY, Zhai M, Xu J, Chen X-Q, Liu W-L, Zhang M, Song S-J, Wang J-M, Meng F-Y, et al. A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi. 2004;43(8):608–10. PMID: 15355668.
   PubMedGoogle Scholar
• Zhou H, Xu M, Qin P, Zhang H-Y, Yuan C-L, Zhao H-G, Cui Z-G, Meng Y-S, Wang L, Zhou F, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541–7. doi:10.1182/blood-2014-06-581868.
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241–8. doi:10.1182/blood.v98.12.3241.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100(10):3457–69. doi:10.1182/blood.V100.10.3457.
   PubMed Web of Science ®Google Scholar
• Townsley DM, Desmond R, Dunbar CE, Young NS. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol. 2013;98(1):48–55. doi:10.1007/s12185-013-1352-6.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang R, Zou P, Hou M, Wu D, Shen Z, Lu X, Li Y, Chen X, Niu T, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222–8. doi:10.1007/s12185-012-1124-8.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282–94. PMID: 25952492.
   PubMed Web of Science ®Google Scholar
• Wang H, Dong Q, Fu R, Qu W, Ruan E, Wang G, Liu H, Wu Y, Song J, Xing L, et al. Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy. Biomed Res Int. 2015;2015(1):2314–6133. doi:10.1155/2015/597293.
   Google Scholar
• Hou M, Hu Y. Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020). Zhonghua Xue Ye Xue Za Zhi. 2020;41(8):617–23. doi:10.3760/cma.j.issn.0253-2727.2020.08.001.
   PubMedGoogle Scholar
• Wen B, Zhang X, Chen S, Fan J, Yang S, Cai Y, Wang P, Zhang Q, Gu Q, Du X, et al. Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: a prospective, non-inferiority, randomized controlled trial. Hematol Oncol. 2022;40(4):777–86. doi:10.1002/hon.3017.
   PubMed Web of Science ®Google Scholar
• Mei H, Xu M, Yuan G, Zhu F, Guo J, Huang R, Qin J, Lv T, Qin F, Cai H, et al. A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients. Br J Haematol. 2021;195(5):781–9. doi:10.1111/bjh.17808.
   PubMed Web of Science ®Google Scholar
• Liu X, Huang Y, Liu W, Chen Y, Xue F, Zhang L, Yang R. Clinical analysis of recombinant human thrombopoietin for 92 adults with severe primary immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi. 2015;36(4):312–5. doi:10.3760/cma.j.issn.0253-2727.2015.04.011.
   PubMedGoogle Scholar
• Angchaisuksiri P, Carlson PL, Dessypris EN. Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. Br J Haematol. 1996;93(1):13–17. doi:10.1046/j.1365-2141.1996.4761013.x.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang R, Han P, Zhao Y, Li G, Li G, Nie M, Wang L, Chen J, Liu X, et al. Effect of recombinant human thrombopoietin on immune thrombocytopenia in pregnancy in a murine model. Int Immunopharmacol. 2019;67(2019):287–93. doi:10.1016/j.intimp.2018.12.032.
   PubMedGoogle Scholar
• Liu X, Bai Y, Wang T, Song Y, Sun F, Xia R, Zhu F, Ma J, Lu Q, Ye X, et al. Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study. Platelets. 2023 Dec 1;34(1):1–8. doi:10.1080/09537104.2022.2157806.
   Web of Science ®Google Scholar
• Wang X, Xu Y, Gui W, Hui F, Liao H. Retrospective analysis of different regimens for Chinese adults with severe newly diagnosed immune thrombocytopenia. Clin Exp Med. 2020;20(3):381–5. doi:10.1007/s10238-020-00630-7.
   PubMed Web of Science ®Google Scholar
• Yu Y, Hou Y, Zhao Y, Zhou H, Jing F, Liu Y, Peng J, Liu X, Hou M. Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. Br J Haematol. 2021;194(1):191–4. doi:10.1111/bjh.17510.
   PubMed Web of Science ®Google Scholar